Acorda Therapeutics(ACOR) - 2023 Q2 - Quarterly Report

we UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3831168 (State or other jurisdiction o ...